Compass Therapeutics at Guggenheim conference: tovecimig faces FDA test

🌐 Investing.com (Cyprus) —
Compass Therapeutics at Guggenheim conference: tovecimig faces FDA test

AI Summary

Compass Therapeutics presented at the Guggenheim healthcare conference, where attention focused on tovecimig and its upcoming FDA evaluation. The headline does not provide further information about the review or the drug’s prospects.

Markets Health Compass Therapeutics tovecimig FDA drug review healthcare conference

Read original source →